Effectiveness and Safety of Ravulizumab in Generalized Myasthenia Gravis (gMG): Updated Analysis from a Global Registry (P1-11.014)
To assess updated effectiveness and safety data for the complement protein C5 inhibitor therapy (C5IT) ravulizumab among patients with gMG in routine clinical practice.
Authors
- Andrew M. Gordon (ORCID: https://orcid.org/0000-0003-1041-0479)
- Pushpa Narayanaswami (ORCID: https://orcid.org/0000-0002-9412-7349)
- Francesco Saccà (ORCID: https://orcid.org/0000-0002-1323-6317)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Samir Macwan
- Lida Zeinali
- James Winkley
- Vern C. Juel (ORCID: https://orcid.org/0000-0002-2917-2995)
- Rup Tandan
- Chuang LIU (ORCID: https://orcid.org/0000-0002-2445-0845)
- Michael Pulley (ORCID: https://orcid.org/0000-0003-1879-725X)
Institutions
- University of North Carolina at Chapel Hill (US)
- Duke University (US)
- Hadassah Medical Center (IL)
- University of Vermont Medical Center (US)
- University of Florida (US)
- Endocrinology Northwest (US)
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208771
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39